Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors. | Drug Deliv | 2026 | 42557654 | PubTator, text mining | PubMed |
| Assessment of Trophoblast cell surface antigen 2 (Trop-2) expression and its clinical significance in breast cancer: a multi-level analysis of protein and gene expression. | BMC Med | 2026 | 42557566 | PubTator, text mining | PubMed |
| TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. | Future Oncol | 2026 | 42535874 | PubTator, text mining | PubMed |
| Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis. | Front Oncol | 2026 | 42534809 | PubTator, text mining | PubMed |
| Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges. | EClinicalMedicine | 2026 | 42534594 | PubTator, text mining | PubMed |
| An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer. | Cell Rep Med | 2026 | 42526440 | PubTator, text mining | PubMed |
| In vitro evaluation of sacituzumab govitecan in non-small cell lung cancer with actionable genomic alterations. | Transl Oncol | 2026 | 42526386 | PubTator, text mining | PubMed |
| Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets. | ESMO Open | 2026 | 42526179 | PubTator, text mining | PubMed |
| Efficacy and safety of TROP2 antibody-drug conjugate-containing regimen in the patients with HER2 negative metastatic breast cancer and advanced non-small-cell lung cancer. | J Chemother | 2026 | 42525843 | PubTator, text mining | PubMed |
| TROP2, Cyclin D1, and Ki-67 as Prognostic Markers of Aggressive Pituitary Adenoma. | Appl Immunohistochem Mol Morphol | 2026 | 42523159 | PubTator, text mining | PubMed |
| Detection of Metastatic Lesions in Esophageal Cancer Using a TROP2 Antibody-Based Near-Infrared Probe. | Adv Healthc Mater | 2026 | 42521344 | PubTator, text mining | PubMed |
| Squamous cell carcinoma of the bladder: Current evidence, therapeutic challenges, and research perspectives from the French AVENTUR group. | Crit Rev Oncol Hematol | 2026 | 42520864 | PubTator, text mining | PubMed |
| Sacituzumab tirumotecan in an advanced HR+/HER2-breast cancer patient with bone marrow metastasis-induced refractory thrombocytopenia: a case report and literature review. | Front Pharmacol | 2026 | 42518341 | PubTator, text mining | PubMed |
| TROP2 Is Uniformly Expressed in Primary Prostate Cancer but Frequently Reduced in Recurrent Disease. | Cancers (Basel) | 2026 | 42512420 | PubTator, text mining | PubMed |
| Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026-A Narrative Review. | Cancers (Basel) | 2026 | 42512415 | PubTator, text mining | PubMed |
| Immunotherapy and Relevant Antibody-Drug Conjugates in Gynecologic Oncology: Recent Advances, Ongoing Challenges, and Future Directions. | Cancers (Basel) | 2026 | 42512405 | PubTator, text mining | PubMed |
| Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder. | Oncol Res | 2026 | 42500580 | PubTator, text mining | PubMed |
| BHLHE40/DEC1 programs epidermal Langerhans cell identity. | J Invest Dermatol | 2026 | 42492657 | PubTator, text mining | PubMed |
| An Overview of Emerging Trends in Targeted Therapy of Triple-Negative Breast Cancer. | Int J Breast Cancer | 2026 | 42488779 | PubTator, text mining | PubMed |
| The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy. | Front Oncol | 2026 | 42488113 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=4